Otros idiomas Cybin Inc. OTC Markets

Acciones

CLXP.F

CA23256X1006

Precio de cierre OTC Markets Otros sitios de cotización 00:00:00 01/09/2021			Varia. Cinco días.	Varia. 1 de enero.
2,63 ^CAD	-6,07 %		+17,41 %	+76,51 %

15/03	Actualización del sector: Los valores del sector sanitario bajan el viernes por la tarde	MT
15/03	Cybin inicia un estudio de prueba de concepto de fase 2 en el trastorno de ansiedad generalizada	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Cybin to Participate at the 27th Annual Milken Institute Global Conference	25/04
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry	18/04
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	17/04
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	16/04
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder	16/04
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	10/04
Cybin : MATERIAL CHANGE REPORT - Form 6-K	22/03
Cybin : AGENCY AGREEMENT - Form 6-K	21/03
Cybin Inc. announced that it has received $150 million in funding from a group of investors	19/03
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas	18/03
Sector Update: Health Care Stocks Softer Friday Afternoon	15/03
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	15/03
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder	15/03
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	15/03
Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO	15/03
Cybin berichtet über ein positives Treffen mit der FDA zum Ende der Phase 2 für CYB003 bei schweren depressiven Störungen und über die Planung eines Programms der Phase 3	14/03
Cybin annonce une réunion positive avec la FDA à la fin de la phase 2 pour le CYB003 dans le trouble dépressif majeur et la conception du programme de phase 3	14/03
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial	14/03
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	14/03
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	14/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Cybin Inc. OTC Markets

Acciones

CLXP.F

CA23256X1006

Otros idiomas

Filtros